

RIBER

Press release –2009 1st half-year results
Bezons, France, August 28, 2009; 5.45 PM

GROWTH IN HALF-YEAR RESULTS

Bezons, France, August 28, 2009 – 17h45 – RIBER, the global leader for molecular beam epitaxy (MBE), reports a further improvement in its performance over the 1st half-year 2009 compared to 2008:

- 13% sales growth
- Net loss divided by 7
- Cash position: € 3.2 million (increased to € 5.2 million at the end of July)
- Sales order backlog up 17%

(€ millions - at 30 June)	HY1 2009 (UNAUDITED)	HY1 2008	change	2008
Sales	5.88	5.19	+13%	19.25
Gross profit	1.59	0.95	+68%	6.46
as % of sales	27.1%	18.3%		33.6%
EBITDA	(0.87)	(1.71)	+48%	+1.1
as % of sales	(15%)	(33%)		5.5%
Operating loss (EBIT)	(0.41)	(1.98)	€ 1.57 m	(0.88)
as % of sales	(7.0%)	(38.1%)		(4.6%)
Loss before tax	(0.36)	(2.17)	€ 1.81 m	(0.93)
Net loss	(0.36)	(2.26)	€ 1.90 m	(1.02)

* EBITDA = Operating income/(loss) + provision, amortization and depreciation charges

2009 HY1 PERFORMANCE

2009 1st half-year consolidated sales increased by 13% to € 5.9 million. Growth was driven by system sales to research centers and universities (5 systems sold, compared to 4 in the 1st half-year 2008), while the demand for systems dedicated to compound semi-conductor manufacturers remained depressed, in line with the economic crisis. Growth was due to sales to research laboratories in Asia, where Riber has long been established. This region accounted for 47% of 1st half-year sales.

Gross profit, excluding non-recurring items amounted to € 1.8 million, or 29% of sales, compared with a profit margin of 26% the previous year. This improvement was due to better terms and conditions on machine sales, procurement rationalization and greater fixed cost absorption.

The consolidated net loss was € 0.4 million, compared with € 2.2 million at 30 June 2008.

At 30 June 2009, the company had a cash position of € 3.2 million, which increased by end July to € 52 million, due to the payment of systems delivered in the 1st half-year and the results of debt collection efforts.

OUTLOOK

Over the period, the sales order backlog increased by 17% compared to the 1st half-year 2008 (to € 6.1 million). It includes 7 research machines to be delivered in 2009, and rising component and service sales.

In line with the 1st half-year performance, Riber's objective is to achieve a net profit over the full 2009 fiscal year.

SHAREHOLDERS' AGENDA: Sales to 30 September 2009, November 5, after close of trading

About RIBER:

Riber designs and produces molecular beam epitaxy (MBE) systems as well as evaporation sources and cells for the semi-conductor industry. This high-technology equipment is essential for the manufacture of compound semi-conductor materials and new materials that are used in numerous consumer applications such as new Information Technologies, OLED flat screens and the new generation of solar cells.

Riber SA's shares are listed in Compartment "C" of the Euronext Paris Stock Exchange and are a component of the CAC IT index.

ISIN Code: FR0000075954 Reuters Code: RIBE.PA Bloomberg Code: RIB.FP

Riber has been awarded the OSEO innovation certification, enabling it to qualify for FCPIs (French mutual funds).

Your contacts:**RIBER**

Olivier Handschumacher

Tel: +33 (0)1 39 96 65 00

e-mail: invest@riber.fr

CALYPTUS

Cyril Combe

Tel: +33 (0)1 53 65 68 68

e-mail: cyril.combe@calyptus.net

www.riber.com